Status:
COMPLETED
Cholinergic Mechanisms of Attention in Aging
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Subjective Cognitive Decline
Eligibility:
All Genders
55+ years
Phase:
EARLY_PHASE1
Brief Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performan...
Detailed Description
Overview: Cognitively normal older adults with and without subjective cognitive decline (SCD) (n = 20; SCD = 10, Non-SCD = 10) will complete two study visits that will be double blinded and randomized...
Eligibility Criteria
Inclusion
- age ≥ 55
- Montreal Cognitive Assessment (MoCA) \> 25 AND Global Deterioration Scale (GDS) rating \< 3
- Non-smokers
Exclusion
- medical contraindications to the drug challenge
- primary neurological disorder (such as stroke, epilepsy, etc.)
Key Trial Info
Start Date :
April 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04756232
Start Date
April 21 2022
End Date
May 1 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212